Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.

Disclosure Of Dealings Under Rule 22 Of The Takeovers Code

Announcements and Notices - [Inside Information]

Inside Information Announcement - Collaboration And License Agreement With Palleon For
E-602 And Combination Therapy

Announcements and Notices - [Announcement by Offeree Company under the Takeovers Code / Announcement by Offeror Company under the Takeovers Code / Privatisation/Withdrawal or Cancellation of Listing of Securities]

Joint Announcement - Fulfilment Of The Pre-Conditions Of
The Proposed Pre-Conditional Privatisation
Of Henlius By Fosun New Medicine
By Way Of Merger By Absorption Of Henlius

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Disclosure Of Dealings Under Rule 22 Of The Takeovers Code

Inside Information Announcement - Collaboration And License Agreement With Palleon For E-602 And Combination Therapy

Disclosure Of Dealings Under Rule 22 Of The Takeovers Code

Disclosure Of Dealings Under Rule 22 Of The Takeovers Code

Joint Announcement - Fulfilment Of The Pre-Conditions Of The Proposed Pre-Conditional Privatisation Of Henlius By Fosun New Medicine By Way Of Merger By Absorption Of Henlius